Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02923726 · ClinicalTrials.gov registry record · NA
Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP
A NA study, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- NA
- Development phase
- 2,692
- Enrollment target
NCT02923726 is a NA study that has completed, run by Boston Scientific Corporation. The registered enrollment target is 2,692 participants.
The verdict
NCT02923726, a NA study, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 2,692 participants
- Enrollment target
Study Summary
The primary objective is to understand the role of antitachycardia pacing (ATP) in primary prevention patients indicated for implantable cardioverter-defibrillator (ICD) therapy and programmed according to current guidance of higher rate cut-offs and therapy delays. The time to first all-cause shock will be tested in subjects with standard therapy (ATP and shocks) compared to subjects programmed to shock only to assess equivalency.
Interventions
- DEVICE Arm 1 (ATP+Shock)
- DEVICE Arm 2 (shock only)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,692 participants |
| Start Date | 2016-09-30 |
| Est. Completion | 2023-07-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02923726
The ClinicalTrials.gov registry entry for NCT02923726 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 2,692 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Arm 1 (ATP+Shock) is the first listed.
NCT02923726 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02923726 about?
NCT02923726 is a clinical study titled "Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP". The primary objective is to understand the role of antitachycardia pacing (ATP) in primary prevention patients indicated for implantable cardioverter-defibrillator (ICD) therapy and programmed according to current guidance of higher rate cut-offs and therapy delays. The time to first all-cause shock...
What is the current status of trial NCT02923726?
This trial is currently completed. It is a NA study. The enrollment target is 2,692 participants. The study started on 2016-09-30. Estimated completion is 2023-07-06.
What interventions are being tested in trial NCT02923726?
The interventions under investigation include: Arm 1 (ATP+Shock) (DEVICE), Arm 2 (shock only) (DEVICE).
Who is sponsoring clinical trial NCT02923726?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.